newsfilter
← Latest News
Business Wire·

LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death

— New Analysis of the AURORA 1 Phase 3 Study Presented at EULAR 2026 Congress — Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced that a new analysis of the AURORA 1 Phase 3 study of LUPKYNIS® in the